Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 330

Sort by

Sort Order Select

Journal Articles

Early assessment of clofarabine effectiveness based on measurable residual disease, including AML stem cells

Diana Hanekamp, Lok Lam Ngai, Jeroen J. W. M. Janssen, Arjan van de Loosdrecht, Gert J. Ossenkoppele, Jacqueline Cloos

Blood (2021) 137 (12): 1694–1697.

https://doi.org/10.1182/blood.2020007150

Published: 2021

Includes: Supplemental data

Journal Articles

Profound Lymphopenia at the Time of ATG Administration Is Not Predictive of Survivals after Allotransplant Using Purine Analogue/Busulfan-Based Conditioning Regimen

Blood (2019) 134 (Supplement_1): 1985.

https://doi.org/10.1182/blood-2019-122013

Published: 2019

Journal Articles

Ptcy + ATG Vs Ptcy Alone As Gvhd Prophylaxis for Peripheral Blood Stem Cells Haplo-Transplants: Comparison of NK and T Cell Effector Reconstitution

Catherine Willem, Thierry Guillaume, MD PhD, Dhon Romeo Makanga, Nolwenn Legrand, Anne Cesbron, PharmD, Katia Gagne, Pierre Peterlin, Alice Garnier, MD, Amandine Le Bourgeois, MD, Marie C Bene, PharmSci, PhD, Patrice Chevallier, MD, Christelle Retière, PhD

Blood (2019) 134 (Supplement_1): 1999.

https://doi.org/10.1182/blood-2019-130822

Published: 2019

Journal Articles

Retrospective Review of Appropriate Use of Antimicrobials and Anticoagulants in Patients Hospitalized for a Malignant Hematologic Condition

Louis-Bassett Porter, MD, Hanaa Shihadeh, Kim Dittus, MD PhD

Blood (2019) 134 (Supplement_1): 2116.

https://doi.org/10.1182/blood-2019-121534

Published: 2019

Journal Articles

The Combination of Venetoclax and Tofacitinib Induced Hematological Responses in Patients with Relapse/ Refractory T-ALL with BCL2 Expression and Surface IL7R Expression or IL7R-Pathway Mutations (On behalf of the GRAALL)

Aurélie Cabannes, MD, Aline Schmidt, MD, Eolia Brissot, MD PhD, Marie Balsat, MD, Sébastien Maury, MD PhD, Francoise Isnard, MD PhD, Patrice Chevallier, MD, Victoria Cacheux, Thomas Cluzeau, MD PhD, Carlos Graux, Ludovic Lhermitte, MD PhD, Herve Dombret, MD PhD, Nicolas Boissel, MD PhD, Vahid Asnafi, MD PhD, Philippe Rousselot, MD PhD

Blood (2019) 134 (Supplement_1): 1339.

https://doi.org/10.1182/blood-2019-130818

Published: 2019

Journal Articles

A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS

Blood (2019) 134 (Supplement_1): 257.

https://doi.org/10.1182/blood-2019-124921

Published: 2019

Journal Articles

Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study

Blood (2019) 134 (Supplement_1): 115.

https://doi.org/10.1182/blood-2019-129876

Published: 2019

Journal Articles

Ptcy + ATG Compared to Ptcy Alone As Gvhd Prophylaxis for Peripheral Blood Stem Cells Allotransplant Is Associated with Significant Lower Incidence of Acute Gvhd without Increasing Relapse or Death By Infection

Patrice Chevallier, MD, Pierre Peterlin, Alice Garnier, MD, Amandine Le Bourgeois, MD, Beatrice Mahe, MD, Viviane Dubruille, MD, Nicolas Blin, MD, Cyrille Touzeau, MD, Thomas Gastinne, MD, Anne Lok, MD, Benoit Tessoulin, MD PhD, Yannick Le Bris, PharmD, Marie C Bene, PharmSci, PhD, Steven Le Gouill, MD PhD, Philippe Moreau, MD, Thierry Guillaume, MD PhD

Blood (2019) 134 (Supplement_1): 4528.

https://doi.org/10.1182/blood-2019-125787

Published: 2019

Journal Articles

Reduced Intensity Conditioning and Dual T-Cell Modulation Improves Gvhd Free, Relapse Free Survival in AML Patients Compared with Myeloablative Conditioning

Maria Queralt Salas, MD, Shiyi Chen, Wilson Lam, MD, David Loach, MD, Fotios V. Michelis, MD PhD, Zeyad Al-Shaibani, Dennis Dong Hwan Kim, MD PhD, Jeffrey H. Lipton, MD PhD, Auro Viswabandya, MDDM, Rajat Kumar, MD, Jonas Mattsson, MD, Arjun Law, MDDM

Blood (2019) 134 (Supplement_1): 4590.

https://doi.org/10.1182/blood-2019-126236

Published: 2019

Journal Articles

High Dose Flamsa, CLAG or FLAG-Based Sequential Conditioning Regimen Followed By Allogeneic Hematopoietic Transplantation Results in Favorable Outcome for High Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasia Patients: A Multicenter Study in Singapore

Yin Jie Koh, Michelle Poon, MBBS, MRCP, FRCPATH, Yeh Ching Linn, MBBS, MRCP, William YK Hwang, MBBS, FRCP, Elson Neo, Aloysius YL Ho, MBBS,FRCP,FRCPath, Lip Kun Tan, MBBS, FRCP, FRCPath, Liang Piu Koh, MBBS, MRCP

Blood (2019) 134 (Supplement_1): 4509.

https://doi.org/10.1182/blood-2019-125246

Published: 2019

Journal Articles

Immunomodulation with Azacytidine and Donor Lymphocyte Infusion Following Sequential Conditioning Allogenic Stem Cell Transplantation Improves Outcome of Unfavorable AML

Magalie Joris, Delphine Lebon, MD, Amandine Charbonnier, MD, Pierre Morel, MD, Berengere Gruson, MD, Alexis Caulier, MD, Caroline Delette, MD, Marie-Noëlle Lacassagne, Nicolas Guillaume, Loïc Garçon, Jean-Pierre Marolleau, MD PhD

Blood (2019) 134 (Supplement_1): 4600.

https://doi.org/10.1182/blood-2019-131314

Published: 2019

Journal Articles

CBFA2T3-GLIS2 Fusion Gene Cause Dismal Clinical Course in Acute Megakaryocytic Leukemia of Down Syndrome

Nao Takasugi, Kenichi Amano, Yasuo Kubota, MD, Shota Kato, MD, Yuichi Mitani, MD, Junya Fujimura, MD PhD, Junko Takita, MD PhD, Mitsuteru Hiwatari, MD PhD

Blood (2019) 134 (Supplement_1): 5184.

https://doi.org/10.1182/blood-2019-129165

Published: 2019

Journal Articles

Multi-Center Retrospective Evaluation of High-Dose Cytarabine Based Induction Versus CPX-351 Induction in Patients with Secondary AML

Lydia Benitez, PharmD, Anthony J. Perissinotti, PharmD, Caitlin R. Rausch, PharmD, Jeff Klaus, PharmD, Stephen Michael Clark, PharmD, Michael Filtz, PharmD, Kelley L Ratermann, PharmD, Carissa F. Treptow, PharmD, Shawn Griffin, PharmD, Marissa Olson, PharmD, Mallory Crain, PharmD, Kristen Pettit, MD, Patrick W. Burke, MD, Dale L. Bixby, MD, Bernard Lawrence Marini, PharmD

Blood (2019) 134 (Supplement_1): 2639.

https://doi.org/10.1182/blood-2019-122189

Published: 2019

Journal Articles

Prognostic Value of Lymphopenia and Lymphocytosis after Peripheral Blood Haplo-Identical Stem Cell Transplantation

Yannick LE Bris, PharmD, Thierry Guillaume, MD PhD, Camille Debord, PharmD, Pierre Peterlin, Soraya Wuilleme, PharmD, PhD, Céline Bressollette, MD PhD, Amandine Le Bourgeois, MD, Alice Garnier, MD, Aurélie Fantou, PharmD, Marie Audrain, MD PhD, Audrey Ménard, Nelly Robillard, PhD, Marion Eveillard, Steven Le Gouill, Berthe Marie Imbert, PharmD, PhD, Marie C Bene, PharmSciD, PhD, Patrice Chevallier, MD

Blood (2019) 134 (Supplement_1): 3319.

https://doi.org/10.1182/blood-2019-122093

Published: 2019

Journal Articles

Multi-Parametric Single Cell Profiling Defines Distinct Drug Responses in Healthy Hematological Cell Lineages That Are Retained in Corresponding Malignant Cell Types

Muntasir M Majumder, MSc, BPharm, Maija Leppä, MSc(Tech), Monica Hellesoy, PhD, Paul Dowling, BSc, PhD, Alina Malyutina, Despina Bazou, BSc, MSc, PhD, Emma Irene Andersson, MSc, Alun Parsons, Jing Tang, PhD, Olli Kallioniemi, MD PhD, Satu Mustjoki, MDPhD, Peter O'Gorman, MD PhD FRCP, FRCPath, Krister Wennerberg, PhD, Kimmo Porkka, MD PhD, Bjorn Gjertsen, MD PhD, Caroline A Heckman, PhD

Blood (2018) 132 (Supplement 1): 264.

https://doi.org/10.1182/blood-2018-99-118242

Published: 2018

Journal Articles

FLT3-ITD Mutations Are Prevalent and Significantly Impact Outcome after Intensive Therapy in Elderly Adults with Acute Myeloid Leukemia (AML): Analysis of the North American Intergroup E2906 Phase III Trial in Patients Age ≥60 Years

James M. Foran, MD, Zhuoxin Sun, PhD, Elisabeth Paietta, PhD, Janis Racevskis, PhD, David F. Claxton, MD, Hillard M Lazarus, MD, Daniel A. Arber, MD, Jacob M. Rowe, MD, John Godwin, MD, Yanming Zhang, MD, Martin S. Tallman, MD, Mark R. Litzow, MD, Keith W. Pratz, MD, Selina Luger, MD

Blood (2018) 132 (Supplement 1): 3995.

https://doi.org/10.1182/blood-2018-99-117838

Published: 2018

Journal Articles

Characterization of Genomic Landscape and Risk Stratification of De Novo Cytogenetically Normal Acute Myeloid Leukaemia

Blood (2018) 132 (Supplement 1): 5267.

https://doi.org/10.1182/blood-2018-99-118909

Published: 2018

Journal Articles

Clofarabine with Topotecan, Vinorelbine, and Thiotepa (TVTC) in Children and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia

Kavitha Ramaswamy, MD, Christopher Forlenza, MD, Rachel Kobos, MD, Peter G. Steinherz, MD, Neerav Shukla, MD

Blood (2018) 132 (Supplement 1): 79.

https://doi.org/10.1182/blood-2018-99-115185

Published: 2018

Journal Articles

No Influence of Peripheral Blood CD34+ and CD3+ Graft Cell Counts on Outcomes after Reduced-Intensity Conditioning Transplantation Using Post-Transplant Cyclophosphamide

Alice Garnier, MD, Thierry Guillaume, MD PhD, Pierre Peterlin, Amandine Le Bourgeois, PhD, Alix Duquesne, Marion Eveillard, PharmD, PhD, Beatrice Mahe, MD, Viviane Dubruille, MD, Nicolas Blin, MD, Cyrille Touzeau, MD PhD, Thomas Gastinne, MD, Anne Lok, MD, Antoine Bonnet, MD, Steven LE Gouill, MD PhD, Philippe Moreau, Marie C Bene, PharmSci, PhD, Patrice Chevallier, MD

Blood (2018) 132 (Supplement 1): 4577.

https://doi.org/10.1182/blood-2018-99-112453

Published: 2018

Journal Articles

Minimal Residual Disease (MRD) at Time of Complete Remission Is Commonly Detected in Acute Myeloid Leukemia (AML) Patients Age ≥60 Years and Significantly Impacts Outcome Based on Post-Remission Treatment Strategies: Prospective Analysis of ECOG-ACRIN (E-A) E2906 Phase III Trial

Blood (2018) 132 (Supplement 1): 437.

https://doi.org/10.1182/blood-2018-99-113950

Published: 2018

NARROW

Early assessment of clofarabine effectiveness based on measurable residual disease, including AML stem cells

Profound Lymphopenia at the Time of ATG Administration Is Not Predictive of Survivals after Allotransplant Using Purine Analogue/Busulfan-Based Conditioning Regimen

Ptcy + ATG Vs Ptcy Alone As Gvhd Prophylaxis for Peripheral Blood Stem Cells Haplo-Transplants: Comparison of NK and T Cell Effector Reconstitution

Retrospective Review of Appropriate Use of Antimicrobials and Anticoagulants in Patients Hospitalized for a Malignant Hematologic Condition

The Combination of Venetoclax and Tofacitinib Induced Hematological Responses in Patients with Relapse/ Refractory T-ALL with BCL2 Expression and Surface IL7R Expression or IL7R-Pathway Mutations (On behalf of the GRAALL)

A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS

Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study

Ptcy + ATG Compared to Ptcy Alone As Gvhd Prophylaxis for Peripheral Blood Stem Cells Allotransplant Is Associated with Significant Lower Incidence of Acute Gvhd without Increasing Relapse or Death By Infection

Reduced Intensity Conditioning and Dual T-Cell Modulation Improves Gvhd Free, Relapse Free Survival in AML Patients Compared with Myeloablative Conditioning

High Dose Flamsa, CLAG or FLAG-Based Sequential Conditioning Regimen Followed By Allogeneic Hematopoietic Transplantation Results in Favorable Outcome for High Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasia Patients: A Multicenter Study in Singapore

Immunomodulation with Azacytidine and Donor Lymphocyte Infusion Following Sequential Conditioning Allogenic Stem Cell Transplantation Improves Outcome of Unfavorable AML

CBFA2T3-GLIS2 Fusion Gene Cause Dismal Clinical Course in Acute Megakaryocytic Leukemia of Down Syndrome

Multi-Center Retrospective Evaluation of High-Dose Cytarabine Based Induction Versus CPX-351 Induction in Patients with Secondary AML

Prognostic Value of Lymphopenia and Lymphocytosis after Peripheral Blood Haplo-Identical Stem Cell Transplantation

Multi-Parametric Single Cell Profiling Defines Distinct Drug Responses in Healthy Hematological Cell Lineages That Are Retained in Corresponding Malignant Cell Types

FLT3-ITD Mutations Are Prevalent and Significantly Impact Outcome after Intensive Therapy in Elderly Adults with Acute Myeloid Leukemia (AML): Analysis of the North American Intergroup E2906 Phase III Trial in Patients Age ≥60 Years

Characterization of Genomic Landscape and Risk Stratification of De Novo Cytogenetically Normal Acute Myeloid Leukaemia

Clofarabine with Topotecan, Vinorelbine, and Thiotepa (TVTC) in Children and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia

No Influence of Peripheral Blood CD34+ and CD3+ Graft Cell Counts on Outcomes after Reduced-Intensity Conditioning Transplantation Using Post-Transplant Cyclophosphamide

Minimal Residual Disease (MRD) at Time of Complete Remission Is Commonly Detected in Acute Myeloid Leukemia (AML) Patients Age ≥60 Years and Significantly Impacts Outcome Based on Post-Remission Treatment Strategies: Prospective Analysis of ECOG-ACRIN (E-A) E2906 Phase III Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only